印度尼西亚人乳头瘤病毒疫苗接种项目的成本分析。

The Cost Analysis of Human Papillomavirus Vaccination Program in Indonesia.

机构信息

Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Purwokerto, Central of Java, Indonesia; Center for Health Economics Studies, Universitas Muhammadiyah Purwokerto, Purwokerto, Central of Java, Indonesia.

Center for Health Economics Studies, Universitas Muhammadiyah Purwokerto, Purwokerto, Central of Java, Indonesia.

出版信息

Value Health Reg Issues. 2023 May;35:102-108. doi: 10.1016/j.vhri.2023.01.005. Epub 2023 Mar 17.

DOI:10.1016/j.vhri.2023.01.005

PMID:36934486

Abstract

OBJECTIVES

This study aimed to analyze and describe the cost of HPV vaccination program in Indonesia.

METHODS

This study identified the cost-related HPV vaccination program implemented in Makassar, Manado, and Surabaya cities, Indonesia, according to the previous activities performed. Cost information was collected and analyzed in each specific activity for each cost components, using the HPV vaccination module of the World Health Organization Cervical Cancer Prevention and Control Costing tool.

RESULTS

According to the Cervical Cancer Prevention and Control Costing tool, the recurrent costs, both financial and economic costs, dominated the HPV vaccination program costs in Surabaya (US dollars [USD] 264 618; USD 268 724), Makassar (USD 166 852; USD 293 300), and Manado (USD 270 815; USD 270 946), with a total cost of USD 702 285 for financial cost and USD 832 970 for economic cost. Vaccine procurement drives the recurrent cost.

CONCLUSIONS

The implementation of demonstration program in Surabaya, Makassar, and Manado cities was considerably succeed. Any prediction related to the cost of implementation of HPV vaccination in Indonesia can be calculated and used to advocate regional or national government.

摘要

目的

本研究旨在分析和描述印度尼西亚 HPV 疫苗接种计划的成本。

方法

本研究根据先前开展的活动，确定了在印度尼西亚的望加锡、万鸦老和泗水三个城市实施的与成本相关的 HPV 疫苗接种计划。使用世界卫生组织宫颈癌防控成本核算工具的 HPV 疫苗接种模块，针对每个特定活动的每个成本构成部分，收集和分析成本信息。

结果

根据宫颈癌防控成本核算工具，在泗水（264618 美元；268724 美元）、望加锡（166852 美元；293300 美元）和万鸦老（270815 美元；270946 美元），反复发生的成本（包括财务成本和经济成本）在 HPV 疫苗接种计划成本中占主导地位，总成本为财务成本 702285 美元，经济成本 832970 美元。疫苗采购推动了反复发生的成本。